Mallinckrodt levorphanol DEA application
Executive SummaryAn Administrative Law Judge has recommended that Mallinckrodt's application for egistration as a bulk mfr. of the Schedule II controlled substance be approved. Roche, the only firm registered by DEA as a levorphanol bulk mfr., objected to Mallinckrodt's application on grounds firm did not have a commercial outlet. The Drug Enforcement Agency explained in an April 29 Federal Register notice that Roxane would like to produce a levorphanol dosage form and asked Mallinckrodt to be a supplier of the bulk product after Roche refused to sell to Roxane.
You may also be interested in...
Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.
Royal Philips is planning to sell its domestic appliance business to better focus on its strategic aims in health technology. The group made the announcement as it unveiled 2019 sales up 4.5% on a comparable basis.
With just under 120 days until the full application of the EU’s Medical Device Regulation, and fears growing of the loss of products seen as non-compliant, the EU medtech industry has identified a way of broadening the application of the “grace period.” It is a legal way of addressing the potential loss of tens of thousands of products come 26 May, says MedTech Europe’s Oliver Bisazza.